Lower incidence of COVID‐19 in patients with inflammatory bowel disease treated with non‐gut selective biologic therapy

Background and Aim Since the outbreak of COVID‐19, concerns have been raised as to whether inflammatory bowel disease (IBD) patients under biologic therapy may be more susceptible to the disease. This study aimed to determine the incidence and outcomes of COVID‐19 in a large cohort of IBD patients o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Gastroenterology and Hepatology 2021-11, Vol.36 (11), p.3050-3055
Main Authors: Ardizzone, Sandro, Ferretti, Francesca, Monico, Maria Camilla, Carvalhas Gabrielli, Anna Maria, Carmagnola, Stefania, Bezzio, Cristina, Saibeni, Simone, Bosani, Matteo, Caprioli, Flavio, Mazza, Stefano, Casini, Valentina, Cortelezzi, Claudio Camillo, Parravicini, Marco, Cassinotti, Andrea, Cosimo, Paola, Indriolo, Amedeo, Di Sabatino, Antonio, Lenti, Marco Vincenzo, Pastorelli, Luca, Conforti, Francesco, Ricci, Chiara, Sarzi‐Puttini, Piercarlo, Vecchi, Maurizio, Maconi, Giovanni
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biologic therapy
Biological Factors - administration & dosage
Biological Therapy - adverse effects
Child
Child, Preschool
Clinical Gastroenterology
Colitis
COVID-19
COVID-19 - epidemiology
Female
Gastroenterology
Humans
Incidence
Infant
Infant, Newborn
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory Bowel Diseases - drug therapy
Inflammatory Bowel Diseases - epidemiology
Intestine
Male
Middle Aged
Patients
Retrospective Studies
Risk factors
SARS-CoV-2
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Since the outbreak of COVID‐19, concerns have been raised as to whether inflammatory bowel disease (IBD) patients under biologic therapy may be more susceptible to the disease. This study aimed to determine the incidence and outcomes of COVID‐19 in a large cohort of IBD patients on biologic therapy. Methods This observational retrospective multicenter study collected data about COVID‐19 in IBD patients on biologic therapy in Italy, between February and May 2020. The main end‐points were (i) to assess both the cumulative incidence and clinical outcome of COVID‐19, according to different biologic agents and (ii) to compare them with the general population and a cohort IBD patients undergoing non‐biologic therapies. Results Among 1816 IBD patients, the cumulative incidence of COVID‐19 was 3.9 per 1000 (7/1816) with a 57% hospitalization rate and a 29% case‐fatality rate. The class of biologic agents was the only risk factor of developing COVID‐19 (P = 0.01). Non‐gut selective agents were associated with a lower incidence of COVID‐19 cases, related symptoms, and hospitalization (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15591